Janssen’s Spravato, a depression treatment, and Novartis’ secondary progressive multiple sclerosis (SPMS) drug Mayzent are not cost-effective, the Institute for Clinical and Economic Review (ICER) suggested in two separate assessments on the therapies.
A Novartis spokesperson tells FiercePharma the report on Mayzent failed to “fully reflect” its feedback provided during the review process. The spokesperson also said Mayzent’s phase 3 trial “demonstrated a significant effect in delaying disability progression in a representative SPMS population.”
To read the full report on FiercePharma, click here.
